|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Veritas Medicine Release: OvaRex MAb For Patients With Advanced Ovarian Cancer May Extend Remission Following Favorable Surgery And Chemotherapy
10/19/2005 5:13:12 PM
BOSTON--(BUSINESS WIRE)--April 4, 2005--
U.S. Researchers Seeking New Standard of Care for Advanced Ovarian Cancer
For the majority of patients with advanced ovarian cancer, the current standard of care and front-line treatments - surgery and chemotherapy - are not enough to control the high recurrence rate. Researchers at clinical centers throughout the United States are further evaluating OvaRex(R) MAb (oregovomab), an investigational therapy, to determine the extent of remission in patients who have a favorable response to surgery and chemotherapy. They are also assessing survival, quality of life, immune response, and safety. Women with stage III or IV ovarian cancer, who qualify to participate in the ongoing clinical research, must begin taking the study medication within four to 12-weeks of completing their last dose of initial chemotherapy. For more information and pre-screening, visit www.OvarianCancerStudy.com.
According to the American Cancer Society (ACS), ovarian cancer causes more deaths than any other cancer of the female reproductive system. Because it is usually detected at an advanced stage, the disease is difficult to treat and most patients relapse within two years of front-line treatment.
|
|
|
|
|
|
|
|
|
|
|